Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19013954 | 0.82 | ALOX5 (0.46) | ALOX5SMN1; SMN2NR1H2LMNAHSD17B10 | |
| SCHEMBL16132316 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1MEN1 | |
| SCHEMBL8611773 | 0.80 | SMN1; SMN2 (0.48) | ALOX5SMN1; SMN2L3MBTL1NR1H2MEN1 | |
| SCHEMBL20148779 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1MEN1 | |
| SCHEMBL16230722 | 0.77 | NR1H2 (0.47) | ALOX5SMN1; SMN2L3MBTL1NR1H2MEN1 | |
| SCHEMBL2037282 | 0.76 | ALOX5 (0.48) | ALOX5SMN1; SMN2L3MBTL1NR1H2MEN1 | |
| SCHEMBL16132367 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1MEN1 | |
| SCHEMBL20148788 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1RAB9A | |
| SCHEMBL20148793 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1CYP3A4CYP17A1MEN1 | |
| SCHEMBL11633055 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1NR1H2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | ALOX5 4211/4885SMN1; SMN2 3797/4885L3MBTL1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.